Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Immunic appoints Inderpal Singh as general counsel » 06:38
06/01/21
06/01
06:38
06/01/21
06:38
IMUX

Immunic

$13.47 /

-0.4 (-2.88%)

, NVS

Novartis

$88.38 /

-0.135 (-0.15%)

Immunic (IMUX) announced…

Immunic (IMUX) announced the appointment of Inderpal Singh as General Counsel. In his new role, Mr. Singh will be responsible for legal and compliance matters and will become part of the management team of Immunic. Mr. Singh joins Immunic from Sandoz International (NVS), where he served as the Global Legal Head of Biopharma since January 2018.

ShowHide Related Items >><<
NVS Novartis
$88.38 /

-0.135 (-0.15%)

IMUX Immunic
$13.47 /

-0.4 (-2.88%)

IMUX Immunic
$13.47 /

-0.4 (-2.88%)

05/07/21 JMP Securities
Immunic price target raised to $56 from $55 at JMP Securities
04/15/21 Piper Sandler
Piper Sandler 'very encouraged' by Immunic Phase 2 EMPhASIS cohort 2 data
04/15/21 Aegis
Immunic initiated with a Buy at Aegis
03/24/21
Fly Intel: Top five analyst initiations
NVS Novartis
$88.38 /

-0.135 (-0.15%)

05/11/21 Morgan Stanley
Novartis price target lowered to CHF 99 from CHF 102 at Morgan Stanley
04/28/21 JPMorgan
Novartis price target lowered to CHF 80 from CHF 85 at JPMorgan
04/28/21 Oddo BHF
Novartis upgraded to Outperform from Neutral at Oddo BHF
04/19/21 UBS
Novartis price target raised to CHF 96 from CHF 95 at UBS
NVS Novartis
$88.38 /

-0.135 (-0.15%)

  • 05
    Aug
  • 10
    Jun
NVS Novartis
$88.38 /

-0.135 (-0.15%)

NVS Novartis
$88.38 /

-0.135 (-0.15%)

IMUX Immunic
$13.47 /

-0.4 (-2.88%)

Over a month ago
Conference/Events
Immunic management to meet virtually with JMP Securities » 04:55
05/18/21
05/18
04:55
05/18/21
04:55
IMUX

Immunic

$13.11 /

+0.67 (+5.39%)

Virtual Meeting to be…

Virtual Meeting to be held on May 18 hosted by JMP Securities.

ShowHide Related Items >><<
IMUX Immunic
$13.11 /

+0.67 (+5.39%)

IMUX Immunic
$13.11 /

+0.67 (+5.39%)

05/07/21 JMP Securities
Immunic price target raised to $56 from $55 at JMP Securities
04/15/21 Piper Sandler
Piper Sandler 'very encouraged' by Immunic Phase 2 EMPhASIS cohort 2 data
04/15/21 Aegis
Immunic initiated with a Buy at Aegis
03/24/21
Fly Intel: Top five analyst initiations
  • 05
    Aug
  • 10
    Jun
IMUX Immunic
$13.11 /

+0.67 (+5.39%)

Conference/Events
Immunic management to meet virtually with JMP Securities » 14:41
05/17/21
05/17
14:41
05/17/21
14:41
IMUX

Immunic

$13.04 /

+0.6 (+4.82%)

Virtual Meeting to be…

Virtual Meeting to be held on May 18 hosted by JMP Securities.

ShowHide Related Items >><<
IMUX Immunic
$13.04 /

+0.6 (+4.82%)

IMUX Immunic
$13.04 /

+0.6 (+4.82%)

05/07/21 JMP Securities
Immunic price target raised to $56 from $55 at JMP Securities
04/15/21 Piper Sandler
Piper Sandler 'very encouraged' by Immunic Phase 2 EMPhASIS cohort 2 data
04/15/21 Aegis
Immunic initiated with a Buy at Aegis
03/24/21
Fly Intel: Top five analyst initiations
  • 05
    Aug
  • 10
    Jun
IMUX Immunic
$13.04 /

+0.6 (+4.82%)

Recommendations
Immunic price target raised to $56 from $55 at JMP Securities » 15:25
05/07/21
05/07
15:25
05/07/21
15:25
IMUX

Immunic

$12.77 /

+0.9 (+7.58%)

JMP Securities analyst…

JMP Securities analyst Gobind Singh raised the firm's price target on Immunic to $56 from $55 and keeps an Outperform rating on the shares. Singh said that the new results from the Phase 2 CALVID-1 trial are "especially important" given independent research published recently that also showed for the first time that immunomodulators/biologics do impair antibody responses to COVID-19 vaccination. The analyst believes MS/IBD drugs that maintain antibody responses like IMU-838 will be "increasingly favored" in a COVID-19 world.

ShowHide Related Items >><<
IMUX Immunic
$12.77 /

+0.9 (+7.58%)

IMUX Immunic
$12.77 /

+0.9 (+7.58%)

04/15/21 Piper Sandler
Piper Sandler 'very encouraged' by Immunic Phase 2 EMPhASIS cohort 2 data
04/15/21 Aegis
Immunic initiated with a Buy at Aegis
03/24/21
Fly Intel: Top five analyst initiations
03/24/21 JMP Securities
Immunic initiated with an Outperform at JMP Securities
  • 05
    Aug
  • 10
    Jun
IMUX Immunic
$12.77 /

+0.9 (+7.58%)

Conference/Events
B. Riley Securities to hold a virtual conference » 04:55
04/29/21
04/29
04:55
04/29/21
04:55
AVXL

Anavex

$12.53 /

+0.2 (+1.62%)

, SEEL

Seelos Therapeutics

$6.31 /

+0.17 (+2.77%)

, IMUX

Immunic

$15.49 /

+0.14 (+0.91%)

Virtual Neuroscience…

Virtual Neuroscience Conference will be held on April 28-29.

ShowHide Related Items >><<
SEEL Seelos Therapeutics
$6.31 /

+0.17 (+2.77%)

IMUX Immunic
$15.49 /

+0.14 (+0.91%)

AVXL Anavex
$12.53 /

+0.2 (+1.62%)

AVXL Anavex
$12.53 /

+0.2 (+1.62%)

02/24/21 Cantor Fitzgerald
Anavex price target raised to $25 from $10 at Cantor Fitzgerald
02/23/21 Cantor Fitzgerald
Anavex price target raised to $25 from $10 at Cantor Fitzgerald
12/29/20 Cantor Fitzgerald
Anavex cash position to fund operations into 2022, says Cantor Fitzgerald
12/16/20 H.C. Wainwright
Anavex price target raised to $17 from $14 at H.C. Wainwright
SEEL Seelos Therapeutics
$6.31 /

+0.17 (+2.77%)

03/30/21
Fly Intel: Top five analyst initiations
03/30/21 B. Riley
Seelos Therapeutics initiated with Buy, $15 target at B. Riley
03/30/21 B. Riley
Seelos Therapeutics initiated with a Buy at B. Riley Securities
03/11/21 BTIG
BTIG starts Seelos Therapeutics at Buy with $14 price target
IMUX Immunic
$15.49 /

+0.14 (+0.91%)

04/15/21 Piper Sandler
Piper Sandler 'very encouraged' by Immunic Phase 2 EMPhASIS cohort 2 data
04/15/21 Aegis
Immunic initiated with a Buy at Aegis
03/24/21
Fly Intel: Top five analyst initiations
03/24/21 JMP Securities
Immunic initiated with an Outperform at JMP Securities
IMUX Immunic
$15.49 /

+0.14 (+0.91%)

AVXL Anavex
$12.53 /

+0.2 (+1.62%)

  • 26
    Jan
  • 05
    Aug
  • 10
    Jun
SEEL Seelos Therapeutics
$6.31 /

+0.17 (+2.77%)

IMUX Immunic
$15.49 /

+0.14 (+0.91%)

AVXL Anavex
$12.53 /

+0.2 (+1.62%)

SEEL Seelos Therapeutics
$6.31 /

+0.17 (+2.77%)

Conference/Events
B. Riley Securities to hold a virtual conference » 09:37
04/28/21
04/28
09:37
04/28/21
09:37
AVXL

Anavex

$12.33 /

+0.01 (+0.08%)

, SEEL

Seelos Therapeutics

$6.14 /

-0.1 (-1.60%)

, IMUX

Immunic

$15.25 /

+0.33 (+2.21%)

Virtual Neuroscience…

Virtual Neuroscience Conference will be held on April 28-29.

ShowHide Related Items >><<
SEEL Seelos Therapeutics
$6.14 /

-0.1 (-1.60%)

IMUX Immunic
$15.25 /

+0.33 (+2.21%)

AVXL Anavex
$12.33 /

+0.01 (+0.08%)

AVXL Anavex
$12.33 /

+0.01 (+0.08%)

02/24/21 Cantor Fitzgerald
Anavex price target raised to $25 from $10 at Cantor Fitzgerald
02/23/21 Cantor Fitzgerald
Anavex price target raised to $25 from $10 at Cantor Fitzgerald
12/29/20 Cantor Fitzgerald
Anavex cash position to fund operations into 2022, says Cantor Fitzgerald
12/16/20 H.C. Wainwright
Anavex price target raised to $17 from $14 at H.C. Wainwright
SEEL Seelos Therapeutics
$6.14 /

-0.1 (-1.60%)

03/30/21
Fly Intel: Top five analyst initiations
03/30/21 B. Riley
Seelos Therapeutics initiated with Buy, $15 target at B. Riley
03/30/21 B. Riley
Seelos Therapeutics initiated with a Buy at B. Riley Securities
03/11/21 BTIG
BTIG starts Seelos Therapeutics at Buy with $14 price target
IMUX Immunic
$15.25 /

+0.33 (+2.21%)

04/15/21 Piper Sandler
Piper Sandler 'very encouraged' by Immunic Phase 2 EMPhASIS cohort 2 data
04/15/21 Aegis
Immunic initiated with a Buy at Aegis
03/24/21
Fly Intel: Top five analyst initiations
03/24/21 JMP Securities
Immunic initiated with an Outperform at JMP Securities
IMUX Immunic
$15.25 /

+0.33 (+2.21%)

AVXL Anavex
$12.33 /

+0.01 (+0.08%)

  • 26
    Jan
  • 05
    Aug
  • 10
    Jun
SEEL Seelos Therapeutics
$6.14 /

-0.1 (-1.60%)

IMUX Immunic
$15.25 /

+0.33 (+2.21%)

AVXL Anavex
$12.33 /

+0.01 (+0.08%)

SEEL Seelos Therapeutics
$6.14 /

-0.1 (-1.60%)

Conference/Events
Cantor Fitzgerald biotech analyst to hold analyst/industry conference call » 09:45
04/27/21
04/27
09:45
04/27/21
09:45
EVGN

Evogene

$4.64 /

+0.15 (+3.34%)

, IMUX

Immunic

$14.92 /

+ (+0.00%)

, GLMD

Galmed

$3.35 /

+0.015 (+0.45%)

Biotech Analyst Kluska,…

Biotech Analyst Kluska, along with President & CEO Vitt of Immunic (IMUX), Chief Scientific Officer Hayardeny at Galmed (GLMD), CEO Haber and VP Meshner at Biomica (subsidiary of Evogene EVGN) discuss emerging targets in development for Inflammatory Bowel Disease (IBD) on an Analyst/Industry conference call to be held on April 27 at 10 am.

ShowHide Related Items >><<
IMUX Immunic
$14.92 /

+ (+0.00%)

GLMD Galmed
$3.35 /

+0.015 (+0.45%)

EVGN Evogene
$4.64 /

+0.15 (+3.34%)

EVGN Evogene
$4.64 /

+0.15 (+3.34%)

11/30/20 Cantor Fitzgerald
Cantor Fitzgerald starts 'highly underappreciated' Evogene at Overweight
11/30/20 Cantor Fitzgerald
Evogene initiated with an Overweight at Cantor Fitzgerald
IMUX Immunic
$14.92 /

+ (+0.00%)

04/15/21 Piper Sandler
Piper Sandler 'very encouraged' by Immunic Phase 2 EMPhASIS cohort 2 data
04/15/21 Aegis
Immunic initiated with a Buy at Aegis
03/24/21
Fly Intel: Top five analyst initiations
03/24/21 JMP Securities
Immunic initiated with an Outperform at JMP Securities
GLMD Galmed
$3.35 /

+0.015 (+0.45%)

11/25/20 Canaccord
Galmed price target lowered to $20 from $25 at Canaccord
05/22/20
Fly Intel: Top five analyst downgrades
05/22/20 B. Riley
B. Riley FBR downgrades Galmed, cuts target to $8 from $11
05/22/20 B. Riley
Galmed downgraded to Neutral from Buy at B. Riley FBR
IMUX Immunic
$14.92 /

+ (+0.00%)

GLMD Galmed
$3.35 /

+0.015 (+0.45%)

  • 05
    Aug
  • 10
    Jun
IMUX Immunic
$14.92 /

+ (+0.00%)

EVGN Evogene
$4.64 /

+0.15 (+3.34%)

Conference/Events
Cantor Fitzgerald biotech analyst to hold analyst/industry conference call » 08:34
04/27/21
04/27
08:34
04/27/21
08:34
EVGN

Evogene

$4.50 /

+0.28 (+6.64%)

, IMUX

Immunic

$14.92 /

+0.38 (+2.61%)

, GLMD

Galmed

$3.35 /

+0.08 (+2.45%)

Biotech Analyst Kluska,…

Biotech Analyst Kluska, along with President & CEO Vitt of Immunic (IMUX), Chief Scientific Officer Hayardeny at Galmed (GLMD), CEO Haber and VP Meshner at Biomica (subsidiary of Evogene EVGN) discuss emerging targets in development for Inflammatory Bowel Disease (IBD) on an Analyst/Industry conference call to be held on April 27 at 10 am.

ShowHide Related Items >><<
IMUX Immunic
$14.92 /

+0.38 (+2.61%)

GLMD Galmed
$3.35 /

+0.08 (+2.45%)

EVGN Evogene
$4.50 /

+0.28 (+6.64%)

EVGN Evogene
$4.50 /

+0.28 (+6.64%)

11/30/20 Cantor Fitzgerald
Cantor Fitzgerald starts 'highly underappreciated' Evogene at Overweight
11/30/20 Cantor Fitzgerald
Evogene initiated with an Overweight at Cantor Fitzgerald
IMUX Immunic
$14.92 /

+0.38 (+2.61%)

04/15/21 Piper Sandler
Piper Sandler 'very encouraged' by Immunic Phase 2 EMPhASIS cohort 2 data
04/15/21 Aegis
Immunic initiated with a Buy at Aegis
03/24/21
Fly Intel: Top five analyst initiations
03/24/21 JMP Securities
Immunic initiated with an Outperform at JMP Securities
GLMD Galmed
$3.35 /

+0.08 (+2.45%)

11/25/20 Canaccord
Galmed price target lowered to $20 from $25 at Canaccord
05/22/20
Fly Intel: Top five analyst downgrades
05/22/20 B. Riley
B. Riley FBR downgrades Galmed, cuts target to $8 from $11
05/22/20 B. Riley
Galmed downgraded to Neutral from Buy at B. Riley FBR
IMUX Immunic
$14.92 /

+0.38 (+2.61%)

GLMD Galmed
$3.35 /

+0.08 (+2.45%)

  • 05
    Aug
  • 10
    Jun
IMUX Immunic
$14.92 /

+0.38 (+2.61%)

EVGN Evogene
$4.50 /

+0.28 (+6.64%)

Syndicate
Immunic files to sell 581,199 shares of common stock for holders  16:34
04/16/21
04/16
16:34
04/16/21
16:34
IMUX

Immunic

$14.22 /

-1.24 (-8.02%)

 
ShowHide Related Items >><<
IMUX Immunic
$14.22 /

-1.24 (-8.02%)

IMUX Immunic
$14.22 /

-1.24 (-8.02%)

04/15/21 Piper Sandler
Piper Sandler 'very encouraged' by Immunic Phase 2 EMPhASIS cohort 2 data
04/15/21 Aegis
Immunic initiated with a Buy at Aegis
03/24/21
Fly Intel: Top five analyst initiations
03/24/21 JMP Securities
Immunic initiated with an Outperform at JMP Securities
IMUX Immunic
$14.22 /

-1.24 (-8.02%)

  • 05
    Aug
  • 10
    Jun
IMUX Immunic
$14.22 /

-1.24 (-8.02%)

Recommendations
Piper Sandler 'very encouraged' by Immunic Phase 2 EMPhASIS cohort 2 data » 10:11
04/15/21
04/15
10:11
04/15/21
10:11
IMUX

Immunic

$14.50 /

+ (+0.00%)

Piper Sandler analyst…

Piper Sandler analyst Yasmeen Rahimi is "very encouraged" by Immunic's Phase 2 EMPhASIS cohort 2 data in RRMS patients, confirming the 30 mg dose selection for an upcoming Phase 3 study in the second half of 2021. Additionally, the analyst highlights Immunic's EMPhASIS presentation at AAN on April 17-22, which is an opportunity to educate physicians about IMU-838. Finally, Rahimi believes any M&A would make the most sense after initiating Phase 3 in MS and having Phase 2 CALDOSE-1 UC data to further bolster IMU-838's value in the eyes of strategics. Rahimi has an Overweight rating and a price target of $71 on the shares.

ShowHide Related Items >><<
IMUX Immunic
$14.50 /

+ (+0.00%)

IMUX Immunic
$14.50 /

+ (+0.00%)

04/15/21 Aegis
Immunic initiated with a Buy at Aegis
03/24/21
Fly Intel: Top five analyst initiations
03/24/21 JMP Securities
Immunic initiated with an Outperform at JMP Securities
02/26/21 Roth Capital
Immunic shares a 'bargain' ahead of 'derisking catalysts,' says Roth Capital
IMUX Immunic
$14.50 /

+ (+0.00%)

  • 05
    Aug
  • 10
    Jun
IMUX Immunic
$14.50 /

+ (+0.00%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.